company background image
SUNPHARMA logo

Sun Pharmaceutical Industries NSEI:SUNPHARMA Stock Report

Last Price

₹1.70k

Market Cap

₹4.0t

7D

-1.1%

1Y

16.5%

Updated

29 May, 2025

Data

Company Financials +

Sun Pharmaceutical Industries Limited

NSEI:SUNPHARMA Stock Report

Market Cap: ₹4.0t

SUNPHARMA Stock Overview

A generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations and active pharmaceutical ingredients (APIs) in India and internationally. More details

SUNPHARMA fundamental analysis
Snowflake Score
Valuation2/6
Future Growth1/6
Past Performance3/6
Financial Health6/6
Dividends4/6

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Sun Pharmaceutical Industries Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for Sun Pharmaceutical Industries
Historical stock prices
Current Share Price₹1,699.80
52 Week High₹1,960.35
52 Week Low₹1,377.20
Beta0.39
1 Month Change-5.85%
3 Month Change6.69%
1 Year Change16.50%
3 Year Change97.75%
5 Year Change243.50%
Change since IPO83,514.62%

Recent News & Updates

Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Due To Pay A Dividend Of ₹5.50

May 25
Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Due To Pay A Dividend Of ₹5.50

Here's Why We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Well Worth Watching

May 15
Here's Why We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Well Worth Watching

Recent updates

Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Due To Pay A Dividend Of ₹5.50

May 25
Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Due To Pay A Dividend Of ₹5.50

Here's Why We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Well Worth Watching

May 15
Here's Why We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Well Worth Watching

Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) Shares May Have Run Too Fast Too Soon

Feb 23
Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) Shares May Have Run Too Fast Too Soon

Analysts Are Updating Their Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Estimates After Its Third-Quarter Results

Feb 05
Analysts Are Updating Their Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Estimates After Its Third-Quarter Results

Sun Pharmaceutical Industries' (NSE:SUNPHARMA) Upcoming Dividend Will Be Larger Than Last Year's

Feb 04
Sun Pharmaceutical Industries' (NSE:SUNPHARMA) Upcoming Dividend Will Be Larger Than Last Year's

Here's Why Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has Caught The Eye Of Investors

Jan 29
Here's Why Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has Caught The Eye Of Investors

Does Sun Pharmaceutical Industries (NSE:SUNPHARMA) Have A Healthy Balance Sheet?

Nov 18
Does Sun Pharmaceutical Industries (NSE:SUNPHARMA) Have A Healthy Balance Sheet?
author-image

Robust Product Pipeline And Market Expansion Drive Growth Amidst Challenges

U.S. and India sales, driven by market leadership and product launches, enhance revenue growth and net margins via economies of scale.

Sun Pharmaceutical Industries Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Oct 31
Sun Pharmaceutical Industries Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

We Ran A Stock Scan For Earnings Growth And Sun Pharmaceutical Industries (NSE:SUNPHARMA) Passed With Ease

Oct 21
We Ran A Stock Scan For Earnings Growth And Sun Pharmaceutical Industries (NSE:SUNPHARMA) Passed With Ease

Pinning Down Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) P/E Is Difficult Right Now

Aug 24
Pinning Down Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) P/E Is Difficult Right Now

Sun Pharmaceutical Industries Limited Just Beat EPS By 10%: Here's What Analysts Think Will Happen Next

Aug 06
Sun Pharmaceutical Industries Limited Just Beat EPS By 10%: Here's What Analysts Think Will Happen Next

This Is The Reason Why We Think Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) CEO Might Be Underpaid

Jul 30
This Is The Reason Why We Think Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) CEO Might Be Underpaid

Sun Pharmaceutical Industries (NSE:SUNPHARMA) Ticks All The Boxes When It Comes To Earnings Growth

Jun 30
Sun Pharmaceutical Industries (NSE:SUNPHARMA) Ticks All The Boxes When It Comes To Earnings Growth

Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has A Rock Solid Balance Sheet

Jun 12
Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has A Rock Solid Balance Sheet

Shareholder Returns

SUNPHARMAIN PharmaceuticalsIN Market
7D-1.1%-0.4%0.5%
1Y16.5%13.1%3.7%

Return vs Industry: SUNPHARMA exceeded the Indian Pharmaceuticals industry which returned 13.1% over the past year.

Return vs Market: SUNPHARMA exceeded the Indian Market which returned 3.7% over the past year.

Price Volatility

Is SUNPHARMA's price volatile compared to industry and market?
SUNPHARMA volatility
SUNPHARMA Average Weekly Movement3.6%
Pharmaceuticals Industry Average Movement7.0%
Market Average Movement6.9%
10% most volatile stocks in IN Market9.6%
10% least volatile stocks in IN Market4.6%

Stable Share Price: SUNPHARMA has not had significant price volatility in the past 3 months compared to the Indian market.

Volatility Over Time: SUNPHARMA's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
198343,000Dilip Shanghviwww.sunpharma.com

Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers formulations in various therapeutic areas, including central nervous system, dermatology, cardiology, oncology, neuropsychiatry, gastroenterology, anti-infectives, diabetology, pain/analgesics, vitamins/minerals/nutrients, respiratory, gynaecology, urology, ophthalmology, orthopaedic, nephrology, dental, and other areas. It provides APIs for anti-cancers, peptides, steroids, hormones, and immunosuppressant drugs.

Sun Pharmaceutical Industries Limited Fundamentals Summary

How do Sun Pharmaceutical Industries's earnings and revenue compare to its market cap?
SUNPHARMA fundamental statistics
Market cap₹4.00t
Earnings (TTM)₹109.29b
Revenue (TTM)₹525.78b
37.3x
P/E Ratio
7.8x
P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SUNPHARMA income statement (TTM)
Revenue₹525.78b
Cost of Revenue₹107.47b
Gross Profit₹418.31b
Other Expenses₹309.02b
Earnings₹109.29b

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)45.55
Gross Margin79.56%
Net Profit Margin20.79%
Debt/Equity Ratio2.6%

How did SUNPHARMA perform over the long term?

See historical performance and comparison

Dividends

0.9%
Current Dividend Yield
35%
Payout Ratio

Does SUNPHARMA pay a reliable dividends?

See SUNPHARMA dividend history and benchmarks
When do you need to buy SUNPHARMA by to receive an upcoming dividend?
Sun Pharmaceutical Industries dividend dates
Ex Dividend DateJul 07 2025
Dividend Pay DateAug 08 2025
Days until Ex dividend38 days
Days until Dividend pay date70 days

Does SUNPHARMA pay a reliable dividends?

See SUNPHARMA dividend history and benchmarks

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/29 11:23
End of Day Share Price 2025/05/29 00:00
Earnings2025/03/31
Annual Earnings2025/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Sun Pharmaceutical Industries Limited is covered by 74 analysts. 35 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Prashant NairAmbit Capital
Nitin BhasinAmbit Capital
Sriraam RathiAnand Rathi Shares and Stock Brokers Limited